Flurbiprofen-d3

Flurbiprofen-d3 is the deuterium labeled Flurbiprofen. Flurbiprofen (dl-Flurbiprofen) is a potent, orally active nonsteroidal anti-inflammatory agent (NSAIA/NSAID), with antipyretic and analgesic activities. Flurbiprofen is commonly used for the research of inflammatory diseases, including osteoarthritis and rheumatoid arthritis. Flurbiprofen is a non-selective cyclooxygenase (COX) inhibitor that can be used for the research of colorectal cancer[1][2][3].

Product Specifications

CAS Number

[1185133-81-6]

Product Name Alternative

Dl-Flurbiprofen-d3

UNSPSC

12352005

Hazard Statement

H301, H315, H319, H335, H361

Target

Apoptosis; COX

Type

Isotope-Labeled Compounds

Related Pathways

Apoptosis; Immunology/Inflammation

Field of Research

Inflammation/Immunology; Cancer

Purity

99.87

Solubility

DMSO : ≥ 100mg/mL

Smiles

FC1=CC(C(C(O)=O)C([2H])([2H])[2H])=CC=C1C2=CC=CC=C2

Molecular Formula

C15H10D3FO2

Molecular Weight

247.28

Precautions

H301, H315, H319, H335, H361

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Xiaobo Wang, et al. Flurbiprofen suppresses the inflammation, proliferation, invasion and migration of colorectal cancer cells via COX2. Oncol Lett. 2020 Nov; 20 (5) : 132.|[3]E M Glenn, et al. The pharmacology of 2- (2-fluoro-4-biphenylyl) propionic acid (flurbiprofen) . A potent non-steroidal anti-inflammatory drug. Agents Actions. 1973 Nov;3 (4) :210-6.|[4]Hosoi, T., et al., Flurbiprofen ameliorated obesity by attenuating leptin resistance induced by endoplasmic reticulum stress. EMBO Mol Med, 2014.